http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106492230-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5067 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate | 2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106492230-B |
| titleOfInvention | Function and application of the leukocytic immunity globulin sample receptor B4 in treatment nonalcoholic fatty liver and type II diabetes |
| abstract | The present invention discloses a kind of function and application of LILRB4 gene in fatty liver diabetes conditions.Using LILRB4 knock out mice and wild type C57 mouse as experimental subjects, the Mice model of obesity induced by high fat diet (HFD), the result shows that being compared with wild type C57 mouse, LILRB4-KO mouse weight after HFD does not have significant change, but fasting blood glucose level is higher than control group WT mouse, liver function is significantly worse than WT mouse.Find that LILRB4-KO mouse obviously weakens the tolerance of glucose by intraperitoneal injection glucose tolerance test.Illustrate that the LILRB4-KO mouse adipose liver pathological changes of HFD group are obviously serious from liver weight and liver/weight ratio and lipid components pathological staining result etc., accumulation of lipid dramatically increases.Therefore, LILRB4 can be used as the drug targets of screening treatment fatty liver and/or type-2 diabetes mellitus, and promotor can be used for preparing the drug for the treatment of fatty liver and/or type-2 diabetes mellitus. |
| priorityDate | 2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.